152 related articles for article (PubMed ID: 18654003)
1. Relationship between coronary events and serum cholesterol during 10 years of low-dose simvastatin therapy: long-term efficacy and safety in Japanese patients with hypercholesterolemia in the Japan Lipid Intervention Trial (J-LIT) Extension 10 Study, a prospective large-scale observational cohort study.
Itakura H; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K;
Circ J; 2008 Aug; 72(8):1218-24. PubMed ID: 18654003
[TBL] [Abstract][Full Text] [Related]
2. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT).
Oikawa S; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Atherosclerosis; 2007 Apr; 191(2):440-6. PubMed ID: 16765358
[TBL] [Abstract][Full Text] [Related]
3. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia.
Matsuzaki M; Kita T; Mabuchi H; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2002 Dec; 66(12):1087-95. PubMed ID: 12499611
[TBL] [Abstract][Full Text] [Related]
4. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT).
Mabuchi H; Kita T; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2002 Dec; 66(12):1096-100. PubMed ID: 12499612
[TBL] [Abstract][Full Text] [Related]
5. Primary cardiovascular events and serum lipid levels in elderly Japanese with hypercholesterolemia undergoing 6-year simvastatin treatment: a subanalysis of the Japan lipid intervention trial.
Horiuchi H; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
J Am Geriatr Soc; 2004 Dec; 52(12):1981-7. PubMed ID: 15571531
[TBL] [Abstract][Full Text] [Related]
6. The risk of cardiovascular events in Japanese hypertensive patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Study, a large-scale observational cohort study.
Shimamoto K; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Sasaki J; Itakura H;
Hypertens Res; 2005 Nov; 28(11):879-87. PubMed ID: 16555576
[TBL] [Abstract][Full Text] [Related]
7. Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: sub-analysis of the Japan Lipid Intervention Trial (J-LIT).
Nakaya N; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2005 Sep; 69(9):1016-21. PubMed ID: 16127179
[TBL] [Abstract][Full Text] [Related]
8. Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group.
Itoh T; Matsumoto M; Hougaku H; Handa N; Tsubakihara Y; Yamada Y; Imaizumi M; Hoshi M; Shimazu Y; Hori M; Kawamori R; Ueda N; Fusamoto H; Kamada T
Clin Ther; 1997; 19(3):487-97. PubMed ID: 9220213
[TBL] [Abstract][Full Text] [Related]
9. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients.
Matsuzawa Y; Kita T; Mabuchi H; Matsuzaki M; Nakaya N; Oikawa S; Saito Y; Sasaki J; Shimamoto K; Itakura H;
Circ J; 2003 Apr; 67(4):287-94. PubMed ID: 12655157
[TBL] [Abstract][Full Text] [Related]
10. Begin with the real-world patients of non-goal-achieved hypercholesterolemia in taiwan through the ezetimibe/simvastatin tablet - The BRAVO Study.
Huang JC; Lee TY; Liou MJ; Lin CM; Pei D; Chen ZC; Liu RT; Kwok CF
Curr Med Res Opin; 2011 Aug; 27(8):1645-51. PubMed ID: 21699369
[TBL] [Abstract][Full Text] [Related]
11. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Averna M; Missault L; Vaverkova H; Farnier M; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Taggart W; Brudi P
Diab Vasc Dis Res; 2011 Oct; 8(4):262-70. PubMed ID: 21859750
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
Goldberg AC; Sapre A; Liu J; Capece R; Mitchel YB;
Mayo Clin Proc; 2004 May; 79(5):620-9. PubMed ID: 15132403
[TBL] [Abstract][Full Text] [Related]
13. Gender difference in coronary events in relation to risk factors in Japanese hypercholesterolemic patients treated with low-dose simvastatin.
Sasaki J; Kita T; Mabuchi H; Matsuzaki M; Matsuzawa Y; Nakaya N; Oikawa S; Saito Y; Shimamoto K; Kono S; Itakura H;
Circ J; 2006 Jul; 70(7):810-4. PubMed ID: 16799230
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
15. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
Ose L; Davidson MH; Stein EA; Kastelein JJ; Scott RS; Hunninghake DB; Campodonico S; Insull W; Escobar ID; Schrott HG; Stepanavage ME; Wu M; Tate AC; Melino MR; Mercuri M; Mitchel YB
Clin Cardiol; 2000 Jan; 23(1):39-46. PubMed ID: 10680028
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
[TBL] [Abstract][Full Text] [Related]
18. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia.
Li JJ; Chen MZ; Chen X; Fang CH
Clin Cardiol; 2003 Oct; 26(10):472-6. PubMed ID: 14579918
[TBL] [Abstract][Full Text] [Related]
19. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
[TBL] [Abstract][Full Text] [Related]
20. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.
Degreef LE; Opdam FL; Teepe-Twiss IM; Jukema JW; Guchelaar HJ; Tamsma JT
Eur J Intern Med; 2010 Aug; 21(4):293-6. PubMed ID: 20603038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
